Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:ARA

American Renal Associates (ARA) Stock Price, News & Analysis

American Renal Associates logo

About American Renal Associates Stock (NYSE:ARA)

Advanced Chart

Key Stats

Today's Range
$11.33
$11.52
50-Day Range
$11.46
$11.52
52-Week Range
$5.57
$11.98
Volume
9,831 shs
Average Volume
106,940 shs
Market Capitalization
$397.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

Receive ARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for American Renal Associates and its competitors with MarketBeat's FREE daily newsletter.

ARA Stock News Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
American Renal Associates Holdings, Inc. News
See More Headlines

ARA Stock Analysis - Frequently Asked Questions

American Renal Associates Holdings, Inc. (NYSE:ARA) issued its quarterly earnings data on Wednesday, November, 11th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.06 by $0.09. The business earned $209.69 million during the quarter, compared to the consensus estimate of $211.50 million. American Renal Associates had a negative net margin of 2.04% and a negative trailing twelve-month return on equity of 3.56%.

American Renal Associates (ARA) raised $161 million in an initial public offering (IPO) on Thursday, April 21st 2016. The company issued 7,500,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that American Renal Associates investors own include Zevra Therapeutics (KMPH), Madrigal Pharmaceuticals (MDGL), Exelixis (EXEL), Gilead Sciences (GILD), Spectrum Pharmaceuticals (SPPI), AbbVie (ABBV) and Bristol-Myers Squibb (BMY).

Company Calendar

Last Earnings
11/11/2020
Today
5/05/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Miscellaneous Health & Allied Services
Sub-Industry
N/A
Current Symbol
NYSE:ARA
Fax
N/A
Employees
4,977
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-13,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$822.52 million
Cash Flow
$1.69 per share
Price / Cash Flow
6.80
Book Value
$2.59 per share
Price / Book
4.45

Miscellaneous

Free Float
N/A
Market Cap
$397.94 million
Optionable
Optionable
Beta
1.11
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NYSE:ARA) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners